Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of PF-04950615 in heterozygous familial hypercholesterolemia
2013-002644-87Phase 3Completed
- Sponsor
- Pfizer
- Start
- Nov 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heterozygous familial hypercholesterolemia (HeFH) and hypercholesterolemia comparing PF-04950615 plus background statin therapy with Placebo plus background statin therapy (2 arms). Started Nov 2013; status: completed.
02
Drugs
bococizumab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)hypercholesterolemia
Beyond the preview
Go deeper on 2013-002644-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002644-87.